Selected article for: "acute kidney injury and administration aki"
Author: Wysocki, Jan; Schulze, Arndt; Batlle, Daniel
Title: Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System
  • Document date: 2019_12_17
    • ID: 0vozochc_49
    Snippet: There are several potential indications of our small ACE2 variants for the treatment of kidney disease. In particular, we think that Acute Kidney Injury (AKI) may benefit from the administration of our small ACE2 variants as a way to calm down the kidney RAS, which is overactive in this clinical syndrome. The pathogenesis of AKI is complex, often involving hemodynamic and non-hemodynamic mechanisms [41] [42] [43] [44] . Alterations in the RAS hav.....
    Document: There are several potential indications of our small ACE2 variants for the treatment of kidney disease. In particular, we think that Acute Kidney Injury (AKI) may benefit from the administration of our small ACE2 variants as a way to calm down the kidney RAS, which is overactive in this clinical syndrome. The pathogenesis of AKI is complex, often involving hemodynamic and non-hemodynamic mechanisms [41] [42] [43] [44] . Alterations in the RAS have been shown to contribute to the development of AKI and are associated with adverse outcomes both in experimental and clinical studies [45] [46] [47] [48] [49] [50] . Several components of the kidney RAS, such as urine Angiotensinogen and Ang II, the main active peptide, are increased in experimental AKI caused by ischemia-reperfusion AKI [45] [46] [47] [51] [52] [53] [54] [55] [56] ACE inhibitors (ACEi) and angiotensin receptor antagonists (ARBs) may attenuate renal inflammation, injury and improve renal function in the ischemia-reperfusion model of AKI [57] [58] [59] [60] . Intrarenal Ang II is reportedly elevated in AKI, which may worsen kidney tissue injury independently of its hemodynamic effect that helps maintain renal circulation [61] [62] [63] . Based on these considerations, we are currently studying the effect of ACE2 1-619 in a mouse model of AKI.

    Search related documents:
    Co phrase search for related documents
    • ACE inhibitor and adverse outcome: 1
    • ACE inhibitor and angiotensin receptor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
    • ACE inhibitor and angiotensin receptor antagonist: 1, 2
    • ACE inhibitor and clinical syndrome: 1
    • ACE inhibitor and kidney disease: 1, 2, 3, 4, 5
    • ACE inhibitor and renal function: 1, 2, 3, 4
    • ACE inhibitor and tissue injury: 1
    • ACEi ACE inhibitor and angiotensin receptor: 1, 2, 3, 4, 5, 6, 7, 8
    • ACEi ACE inhibitor and kidney disease: 1
    • ACEi ACE inhibitor and renal function: 1
    • active peptide and angiotensin receptor: 1, 2, 3
    • active peptide and kidney disease: 1, 2
    • active peptide and kidney disease treatment: 1
    • active peptide and main active peptide: 1, 2, 3
    • active peptide and mouse model: 1
    • active peptide and renal function: 1
    • active peptide and renal inflammation: 1, 2
    • adverse outcome and AKI development: 1
    • adverse outcome and angiotensin receptor: 1, 2, 3, 4, 5